Please login to the form below

Not currently logged in
Email:
Password:

Farydak

This page shows the latest Farydak news and features for those working in and with pharma, biotech and healthcare.

Amgen's Kyprolis tops Velcade in myeloma trial

Amgen's Kyprolis tops Velcade in myeloma trial

Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

Latest news

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics